How digital health companies are capitalizing on the GLP-1 boom
Joining the market for GLP-1s is a massive opportunity, and digital health companies from Ro to WeightWatchers are battling for
Read MoreJoining the market for GLP-1s is a massive opportunity, and digital health companies from Ro to WeightWatchers are battling for
Read MoreTargeted radiopharmaceuticals, which deliver radiation directly into tumors, has caught the eye of big pharma. Source link
Read MoreRadiopharmaceuticals seek to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly
Read MorePharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including
Read MoreThe weekly injection helped patients with obesity lose 18.8% of their weight relative to those who received a placebo, after
Read MoreAmgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are progressing on their own treatments. Source link
Read MoreIt won't be long for artificial intelligence can handle drug discovery for pharmaceutical companies without human scientists. Source link
Read MoreThe future direction of Federal Reserve interest rate policy as well as opportunities tied to artificial intelligence remain hot topics
Read MoreAmgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and
Read More